[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vyome Holdings Inc (HIND)

Vyome Holdings Inc (HIND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,476
  • Shares Outstanding, K 7,018
  • Annual Sales, $ 320 K
  • Annual Income, $ -10,260 K
  • EBIT $ -14 M
  • EBITDA $ -14 M
  • 60-Month Beta 1.38
  • Price/Sales 43.43
  • Price/Cash Flow N/A
  • Price/Book 2.97

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-9.00
  • Growth Rate Est. (year over year) +11,200.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.8950 +1.32%
on 05/13/26
2.3800 -19.33%
on 04/20/26
-0.3600 (-15.79%)
since 04/14/26
3-Month
1.8950 +1.32%
on 05/13/26
3.5300 -45.61%
on 02/25/26
-0.6700 (-25.87%)
since 02/13/26
52-Week
1.7500 +9.71%
on 02/02/26
33.1600 -94.21%
on 06/03/25
-22.2800 (-92.07%)
since 05/14/25

Most Recent Stories

More News
Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity

Vyome has signed an agreement with Impetis, a TATA Enterprise, to in-license two selective JAK inhibitor assets, opening access to a large and growing ~$57B global market¹ ...

HIND : 1.9200 (unch)
Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026

VT-1953 topical gel significantly reduced MFW-associated severe malodor over a 14 Day period (P=0.0020) as scored by investigators. VT-1953 efficacy was significantly superior to the vehicle control (P=...

HIND : 1.9200 (unch)
Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026

Complete Phase 2 clinical data on the efficacy and safety of VT-1953 in MFW patients accepted for presentation at the annual meeting of the American Association for Cancer Research

HIND : 1.9200 (unch)
Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase

Completed a streamlined Nasdaq listing through a merger transaction, with a common stock capital structure and no preferred stock or debt Delivered positive...

HIND : 1.9200 (unch)
Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company

Livechain Creates Path to Seek Potential Uplisting to National Exchange in 2026

LICH : 0.0116 (+11.54%)
HIND : 1.9200 (unch)
Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity

VT-1908 was demonstrated to be effective as a topical steroid in the uveitis preclinical model and shows very good safety Plans to generate human clinical...

HIND : 1.9200 (unch)
Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months

Acceptance of Orphan Drug Status would confer certain anticipated US Market Exclusivity, R&D tax benefits, and PDUFA fee waiver of approximately $3M ...

HIND : 1.9200 (unch)
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results

Company Chose Minimal Dilution Path with No Warrants and Has Sufficient Liquidity to Deliver Initial Phase 3 Results for MFW product

HIND : 1.9200 (unch)
Independent Analyst Values Vyome’s VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study

Third-party analysis estimates the total addressable U.S. market to be approximately USD 2.2 billion Modeled peak annual U.S. sales approaching USD 600 million for VT-1953 ...

HIND : 1.9200 (unch)
Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company

Vyome Board completes review of strategic alternatives for LICH, executes critical first step in building a scalable, standalone business

LICH : 0.0116 (+11.54%)
HIND : 1.9200 (unch)

Business Summary

Vyome Therapeutics Inc. is a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases principally in the US. Vyome Therapeutics Inc., formerly known as ReShape Lifesciences Inc., is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 2.0532
2nd Resistance Point 2.0165
1st Resistance Point 1.9683
Last Price 1.9200
1st Support Level 1.8834
2nd Support Level 1.8467
3rd Support Level 1.7985

See More

52-Week High 33.1600
Fibonacci 61.8% 21.1614
Fibonacci 50% 17.4550
Fibonacci 38.2% 13.7486
Last Price 1.9200
52-Week Low 1.7500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.